All In Biotech

Drug Trial Radar · NCT06158841

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 421 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

421

Actual

Start

May 19, 2024

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Dec 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine change in disease symptoms of etentamig compared to standard available therapies in adult participants with relapsed/refractory (R/R) MM. Etentamig is an investigational drug being developed for the treatment of R/R MM. This study is broken into 2 Arms; Arm A and Arm B. In Arm A, participants will receive etentamig as a monotherapy. In Arm B, participants will receive the standard available therapy (SAT) identified by the Investigator during screening, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable. Around 380 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 140 sites across the world. In Arm A participants will receive etentamig as an infusion into the vein in 28 day cycles, during the 3.5 year study duration. In Arm B, participants will receive the SAT identified by the Investigator during screening, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable, during the 3.5 year study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

Conditions

  • Multiple Myeloma

Interventions

  • EtentamigDrug

    Intravenous (IV) Infusion

  • CarfilzomibDrug

    IV Infusion

  • PomalidomideDrug

    Oral Capsule

  • ElotuzumabDrug

    IV Infusion

  • SelinexorDrug

    Oral Tablet

  • BortezomibDrug

    Subcutaneous or IV Injection

  • DexamethasoneDrug

    Oral Tablet or IV Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: Up to Approximately 5 Years
  2. Objective Response Rate (ORR)Time frame: Up to Approximately 5 Years

Locations

166 sites in 25 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham - Main /ID# 261434

    Birmingham, Alabama

  • Mayo Clinic Hospital - Phoenix /ID# 263326

    Phoenix, Arizona

  • Alta Bates Summit Medical Center for Research /ID# 261438

    Berkeley, California

  • Providence - St. Jude Medical Center /ID# 262031

    Fullerton, California

  • VA Loma Linda Healthcare System /ID# 261015

    Loma Linda, California

  • Cedars-Sinai Medical Center /ID# 261008

    Los Angeles, California

  • Rocky Mountain Cancer Centers - Lone Tree /ID# 278320

    Lone Tree, Colorado

  • Mayo Clinic Hospital Jacksonville /ID# 263324

    Jacksonville, Florida

  • Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 246230

    Jacksonville, Florida

  • Winship Cancer Institute of Emory University /ID# 262525

    Atlanta, Georgia

  • University of Illinois Hospital and Health Sciences System /ID# 246349

    Chicago, Illinois

  • Rush University Medical Center /ID# 265690

    Chicago, Illinois

  • Nancy W. Knowles Cancer Center /ID# 271361

    Elmhurst, Illinois

  • Springfield Clinic - First /ID# 262266

    Springfield, Illinois

  • Our Lady Of The Lake Regional Medical Center /ID# 272780

    Baton Rouge, Louisiana

  • Center for Cancer and Blood Disorders-American Oncology Partners of Maryland /ID# 263637

    Bethesda, Maryland

  • Beth Israel Deaconess Medical Center /ID# 271535

    Boston, Massachusetts

  • Dana-Farber Cancer Institute /ID# 261554

    Boston, Massachusetts

  • Regents of the University of Michigan /ID# 261577

    Ann Arbor, Michigan

  • Karmanos Cancer Institute - Detroit /ID# 266298

    Detroit, Michigan

  • Henry Ford Hospital /ID# 262704

    Detroit, Michigan

  • Barbara Ann Karmanos Cancer Institute - McLaren Greater Lansing /ID# 259891

    Lansing, Michigan

  • Mayo Clinic - Rochester /ID# 246228

    Rochester, Minnesota

  • University of Missouri Hospital /ID# 261553

    Columbia, Missouri

  • Nebraska Cancer Specialists - Omaha - Wright Street /ID# 276772

    Omaha, Nebraska

  • New York Cancer & Blood Specialists - Bay Shore /ID# 261524

    Bay Shore, New York

  • New York Cancer & Blood Specialists - Lake Success Medical Oncology /ID# 262953

    New Hyde Park, New York

  • New York Cancer and Blood Specialists - New York /ID# 262951

    New York, New York

  • Eastchester Center for Cancer Care /ID# 262952

    The Bronx, New York

  • University of North Carolina /ID# 259854

    Chapel Hill, North Carolina

  • Atrium Health Levine Cancer Institute /ID# 246199

    Charlotte, North Carolina

  • Duke University Medical Center /ID# 259694

    Durham, North Carolina

  • University Of Cincinnati Medical Center /ID# 246415

    Cincinnati, Ohio

  • Cleveland Clinic Main Campus /ID# 246183

    Cleveland, Ohio

  • Oregon Medical Research Center /ID# 262335

    Portland, Oregon

  • Medical University of South Carolina /ID# 259692

    Charleston, South Carolina

  • University of Tennessee Health Science Center /ID# 261622

    Memphis, Tennessee

  • Baptist Memorial Hospital /ID# 270910

    Memphis, Tennessee

  • The West Clinic /ID# 262444

    Memphis, Tennessee

  • Vanderbilt University Medical Center /ID# 261621

    Nashville, Tennessee

Showing 40 of 166 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.